Pfizer Covid vaccine for young children may not be renewed by FDA Email obtained by Guardian says Pfizer was told approval may not be granted, meaning Moderna may have to fill gap The Guardian - US · Aug 9, 2025
Moderna Is Cutting 10,000 Jobs as Its Business Erodes. How Should You Play MRNA Stock Here? With vaccine revenue crumbling and layoffs in full swing, is Moderna’s slimmed-down strategy a smart move or a red flag for investors? Barchart · Aug 7, 2025
AI is already changing the corporate org chart AI isn't just a new tool for the modern workplace; it's quietly reshaping how companies are organized. Fortune · Aug 7, 2025
Doctors decry RFK Jr decision to slash mRNA vaccine grants: ‘Our nation will pay in lives’ ‘A tremendous step backward, the politicization of science, and RFK Jr., who has been a lifelong anti-vaccine propagandist and science denialist, is now making policy,’ one doctor said The Independent UK · Aug 6, 2025
Despite RFK’s funding block, mRNA vaccines are too impressive to ignore Scientists fear decision may increase vaccine hesitancy, but other countries are still willing to invest in research The Guardian - UK · Aug 6, 2025
RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies' The Department of Health and Human Services will cancel 22 vaccine development projects totaling $500 million, marking a major policy shift under Secretary Robert F. Kennedy Jr. that directly affects pharmaceutical giants like Pfizer Inc. (NYSE:PFE) and Moderna Inc. (NASDAQ:MRNA). Benzinga · Aug 6, 2025
Moderna Stock: Is Wall Street Bullish or Bearish? As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects. Barchart · Aug 6, 2025
Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector Shares of Novavax Inc (NASDAQ:NVAX) are trading lower Friday morning, appearing to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna Inc (NASDAQ:MRNA) reported disappointing second-quarter financial results and cut its full-year forecast. Benzinga · Aug 1, 2025
Moderna's Key Patent Win Overshadowed By Gloomy Outlook Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago. Benzinga · Aug 1, 2025
Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Moderna, Inc. (NASDAQ:MRNA) will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1. Benzinga · Aug 1, 2025
Moderna Announces 10% Workforce Cut Amid Declining COVID-19 Vaccine Sales, Regulatory Hurdles Moderna Inc. (NASDAQ:MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty. Benzinga · Jul 31, 2025
1 Analyst Thinks This Former Pandemic Winner Could Surge 500% This Year This risky biotech company faces significant challenges ahead. But it has already proven its worth and may be able to do so again. Barchart · Jul 29, 2025
What's Going On With Moderna Stock Wednesday? Moderna Inc.’s (NASDAQ:MRNA) stock has surged approximately 37% in the last month but has dipped around 15% year to date. Benzinga · Jul 23, 2025
What to Expect From Moderna's Next Quarterly Earnings Report Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in its losses. Barchart · Jul 14, 2025
The Guardian - US · Jul 12, 2025 ‘Tremendous uncertainty’ for cancer research as US officials target mRNA vaccines Amid Trump cuts and state-level backlash, experts worry that progress in messenger RNA vaccines could stall
Benzinga · Jul 10, 2025 FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.
Barchart · Jul 8, 2025 The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential. This clinical-stage biotech stock has a strong pipeline capable of creating the next Moderna.
The Independent UK · Jul 2, 2025 FDA vaccine official restricted COVID vaccine approvals against the advice of agency staff A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines
The Independent UK · Jun 27, 2025 RFK Jr.'s made promises about vaccines. Here's what he's done as health secretary The Department of Health and Human Services under Robert F
International Business Times UK · Jun 27, 2025 COVID Vaccine Side Effects: FDA Announces Rare Heart-Related Reactions - What You Should Know FDA has updated safety warnings for the Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) COVID-19 vaccines.
Benzinga · Jun 26, 2025 RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts and former federal officials after its first meeting strayed sharply from established scientific review norms.
The Guardian - US · Jun 14, 2025 US experts fear all vaccines at risk as Trump officials target mRNA jabs Administration’s actions signal move away from technology as health agencies see vaccine-related shakeups
Barchart · Jun 6, 2025 How Is Moderna’s Stock Performance Compared to Other Biotechnology Stocks? Moderna has significantly underperformed other biotechnology stocks over the past year, and analysts remain cautious on the stock’s prospects.
Fortune · Jun 2, 2025 What you need to know about Moderna's new COVID vaccine, just approved by the FDA The shot had previously been approved for everyone 12 and older. Now, there are limits.
The Independent UK · May 31, 2025 FDA approves Moderna's new lower-dose COVID-19 vaccine The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it